LLY

1,044.51

-0.34%↓

JNJ

202.86

+0.41%↑

ABBV

229.52

-1.97%↓

UNH

311.09

+1.53%↑

AZN

88.99

-0.06%↓

LLY

1,044.51

-0.34%↓

JNJ

202.86

+0.41%↑

ABBV

229.52

-1.97%↓

UNH

311.09

+1.53%↑

AZN

88.99

-0.06%↓

LLY

1,044.51

-0.34%↓

JNJ

202.86

+0.41%↑

ABBV

229.52

-1.97%↓

UNH

311.09

+1.53%↑

AZN

88.99

-0.06%↓

LLY

1,044.51

-0.34%↓

JNJ

202.86

+0.41%↑

ABBV

229.52

-1.97%↓

UNH

311.09

+1.53%↑

AZN

88.99

-0.06%↓

LLY

1,044.51

-0.34%↓

JNJ

202.86

+0.41%↑

ABBV

229.52

-1.97%↓

UNH

311.09

+1.53%↑

AZN

88.99

-0.06%↓

Search

Simulations Plus Inc

Abierto

SectorSanidad

16.15 0.87

Resumen

Variación precio

24h

Actual

Mínimo

16.05

Máximo

16.53

Métricas clave

By Trading Economics

Ingresos

-70M

-67M

Ventas

-2.1M

20M

P/B

Media del Sector

48.528

106.172

Rentabilidad por dividendo

0.48

Margen de beneficios

-330.585

Empleados

243

EBITDA

327K

5.3M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

-2.02% downside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.48%

2.31%

Próximas Ganancias

1 dic 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-9.6M

342M

Apertura anterior

15.28

Cierre anterior

16.15

Noticias sobre sentimiento de mercado

By Acuity

12%

88%

10 / 374 Clasificación en Healthcare

Simulations Plus Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

19 nov 2025, 23:36 UTC

Acciones populares

Stocks to Watch: Nvidia, Kulicke & Soffa, Regeneron

19 nov 2025, 22:13 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Palo Alto Networks to Buy Chronosphere for $3.35 Billion, Posts Higher 1Q Revenue -- Update

19 nov 2025, 21:55 UTC

Principales Movimientos del Mercado

Amgen Lung Cancer Drug Gets Full Approval From FDA

19 nov 2025, 21:43 UTC

Adquisiciones, fusiones, absorciones

Palo Alto Networks to Buy Chronosphere for $3.35 Billion

19 nov 2025, 23:55 UTC

Charlas de Mercado

Gold Rises on Possible Investment Demand -- Market Talk

19 nov 2025, 23:54 UTC

Charlas de Mercado

BHP Vicuna JV Offers Significant Copper Output, At a Cost -- Market Talk

19 nov 2025, 23:47 UTC

Ganancias

Lenovo Group 2Q EPS $2.52 >0992.HK

19 nov 2025, 23:46 UTC

Ganancias

Lenovo Group: Delivered Double-Digit Yr-on-Yr Rev Growth Across All Main Business Groups and Sales Geographies >0992.HK

19 nov 2025, 23:45 UTC

Ganancias

Lenovo Group 2Q Rev $20.5B >0992.HK

19 nov 2025, 23:42 UTC

Charlas de Mercado

Nikkei May Rise After Nvidia's Strong Earnings Soothe Investors' Nerves -- Market Talk

19 nov 2025, 23:42 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

19 nov 2025, 23:41 UTC

Ganancias

Lenovo Group 2Q Adj Net $512.0M Vs. $409.0M >0992.HK

19 nov 2025, 23:41 UTC

Ganancias

Lenovo Group 2Q Net $340.0M Vs. Net $359.0M >0992.HK

19 nov 2025, 23:40 UTC

Ganancias

Lenovo Group 2Q Rev $20.45B Vs. $17.85B >0992.HK

19 nov 2025, 22:55 UTC

Ganancias

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 4th Update

19 nov 2025, 22:41 UTC

Ganancias

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 3rd Update

19 nov 2025, 22:30 UTC

Adquisiciones, fusiones, absorciones

CICC Seeks Trading Halt in Hong Kong, Shanghai Stock Exchange

19 nov 2025, 22:30 UTC

Ganancias

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- 2nd Update

19 nov 2025, 22:30 UTC

Adquisiciones, fusiones, absorciones

CICC Plans to Acquire Brokerage Firms via Share-Swap Agreement

19 nov 2025, 22:27 UTC

Adquisiciones, fusiones, absorciones

China International Capital Plans to Acquire Brokerage Firms Cinda Securities, Dongxing Securities

19 nov 2025, 22:08 UTC

Ganancias

ZTO Express (Cayman) 3Q Rev $1.67B >ZTO

19 nov 2025, 22:00 UTC

Ganancias

Investors Cheer Blockbuster Nvidia Earnings -- WSJ

19 nov 2025, 21:58 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Palo Alto Networks to Buy Chronosphere for $3.35B, Posts Higher 1Q Rev -- Update

19 nov 2025, 21:52 UTC

Ganancias

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- Update

19 nov 2025, 21:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

19 nov 2025, 21:49 UTC

Charlas de Mercado
Ganancias

Nvidia Quiets Investor Fears With Ballooning Demand -- Market Talk

19 nov 2025, 21:38 UTC

Ganancias

Nvidia Profits Soar, Countering Investor Jitters on AI Boom -- WSJ

19 nov 2025, 21:28 UTC

Adquisiciones, fusiones, absorciones

Palo Alto Networks to Buy Chronosphere for $3.35B

19 nov 2025, 21:27 UTC

Adquisiciones, fusiones, absorciones

Exact Sciences Stock Jumps on Reported Deal Interest from Abbott Laboratories -- Barrons.com

19 nov 2025, 21:24 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Palo Alto Networks 1Q Next-Generation Security ARR $5.9 B >PANW

Comparación entre iguales

Cambio de precio

Simulations Plus Inc previsión

Precio Objetivo

By TipRanks

-2.02% descenso

Estimación a 12 Meses

Media 16 USD  -2.02%

Máximo 16 USD

Mínimo 16 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Simulations Plus Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

2

Comprar

2

Mantener

0

Vender

Sentimiento

By Acuity

10 / 374 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat